Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
23.3.2022 09:39:48 CET | BactiQuant A/S | Investor Nyheder
BactiQuant præciserer information i investor meddelelse udsendt 21.3.2022 14:03:45 CET | BactiQuant A/S | Investor Nyheder
BactiQuant har ved en beklagelig fejl skrevet at Swedish Water Research har undersøgt BactiQuant metoden, med et godt resultat. Der skulle retteligt have stået at undersøgelsen var finansieret af Svenskt Vatten Utveckling (SVU). Projektet: "Enzym i dricksvatten som indikator på bakteriell belastning", blev udført af Biofact Miljømedicinske Forskningscentrum i samarbejde med Nordvästra Skånes vatten og avlopp (NSVA), VA-enheden i Lerums kummune og Sydvatten AB. Misforståelsen er opstået ved at Swedish Water Research er repræsenteret i den kommite som tager stilling til forskningsansøgninger indsendt til SVU.
Kontakter
- John Norden, Certificeret rådgiver til Nasdaq First North, +4520700200, jn@nordencef.dk
- Morten Miller, Chief Innovation Officer (CINO), +4523678732, miller@bactiquant.dk
Om BactiQuant A/S
Bactiquant has developed a technology that will revolutionize the monitoring of bacterial contamination levels in water and ensure optimum usage and handling of water around the world to the benefit of our customers and sustainability of our planet. To show our commitment to the environment, we have aligned our business with four of the UN's Sustainable Development Goals. We believe that Bactiquant will be the world leader within mobile and online surveillance of bacterial contamination levels, and we are already well on our way. Headquartered in Denmark and operating across five continents, our customers come from a wide range of industries such as public water utility companies, industries needing water cooling or requiring wastewater treatment, as well as aquaculture.